PST2238: A new antihypertensive compound that antagonizes the long-term pressor effect of ouabain

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 1, 1998, Pages 83-94

  Ferrari, P ^a,b   Torielli, L ^a   Ferrandi, M ^a   Padoani, G ^a   Duzzi, L ^a   Florio, M ^a   Conti, F ^a   Melloni, P ^a   Vesci, L ^a   Corsico, N ^a   Bianchi, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Prassis Sigma Tau Research Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA (3 FURYL) 5BETA ANDROSTANE 3BETA,14BETA,17ALPHA TRIOL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIHYPERTENSIVE AGENT; OUABAIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HYPERTENSION; KIDNEY CELL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; CELLS, CULTURED; MALE; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 7844239580     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Anner BM, Imesch E and Moosmayer M (1995) Normal sensitivity of Na-K ATPase isolated from brain and kidney of spontaneously hypertensive rats to sodium, ouabain and mercury. Biochim Biophys Acta 1270:95-99.
2. Bagrov A, Kuznetsova E and Fedorova O (1994) Endogenous digoxin-like factor in acute myocardial infarction. J Int Med 235:63-67.
3. Beaumont K, Clilton WS, Yamamura HI and Enna SJ (1978) Muscimol binding in rat brain: Association with synaptic GABA receptors. Brain Res 148:153-162.
4. Blaustein MP (1977) Sodium ions, calcium ions and blood pressure regulation: A reassessment and a hypothesis. Am J Physiol 232:C165-C173.
5. 3H) 5-hydroxytryptamine in the rat CNS. J Neurochem 46:1392.
6. +)-ATPase activity in heart muscle after chronic treatment with digoxin or potassium deficient diet. Eur J Pharmacol 37:189-191.
7. + ATPase expression in cultured renal cells by incubation in Hypertonic medium. Am J Physiol 262:C845-C853.
8. 3H)NECA in rat striatal membranes. Mol Pharmacol 29:331-346.
9. Bylund DB and Snyder SH (1976) Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12:568-580.
10. Catterall WA, Morrow CS and Hartshorne RP (1979) Neurotoxin binding to receptor sites associated with voltage-sensitive sodium channels in intact, lysed and detergent-solubilized brain membranes. J Biol Chem 254:11379-11387.
11. 3HDVP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. Biochem Biophys Res Comm 172:1195-1202.
12. Corvol P, Michaud A, Menard J, Freifeld M and Mahoudeau J (1975) Antiandrogenic effect of spironolactones: Mechanisms of action. Endocrinology 97:52-58.
13. De Larco JE and Todaro GJ (1978) Epithelioid and fibroblastic rat kidney cell clones: Epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation. J Cell Physiol 94:335-342.
14. De Mendoca M, Grichois ML, Pernollet MG, Wauquier I, Trouillet-Thormann B, Meyer P, Devynck MA and Garay R (1988) Antihypertensive effect of Canrenone in a model where endogenous ouabain-like factors are present. J Cardiovasc Pharmacol 11:75-83.
15. Delva P, Devynck MA, Degan M, Pernollet MG, Carraroli M, Capra C, Steele A and Lechi A (1991) Plasma levels of an endogenous Na-K pump inhibitor in relation to haemodynamic data in cardiopathic patients. Clin Sci 81:23-29.
16. Doris PA (1994) Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 266:H360-H364.
17. Doucet A, Kats I and Morel F (1979) Determination of Na-K-ATPase activity in single segments of mammalian nephron. Am J Physiol 237:F105-F113.
18. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G and Ferrari P (1997) Ouabain-like factor quantification in mammalian tissues and plasma: Comparison of two independent assays. Hypertension 30(4):886-896.
19. Ferrandi M, Minotti E, Salardi S, Florio M, Bianchi G and Ferrari P (1992) Ouabain-like factor in Milan hypertensive rats. Am J Physiol 263:F739-F78.
20. Ferrandi M, Tripodi G, Salardi S, Florio M, Modica R, Barassi P, Parenti P, Shainskaya A, Karlish S, Bianchi G and Ferrari P (1996) Renal Na-K ATPase in genetic hypertension. Hypertension 28:1018-1025.
21. Ferrari P (1995) A new selective antagonist of the ouabain pressor effect (Abstract). Proceedings of the 1st European Congress of Pharmacology. Pharmacol Res 31S: 323.
22. 3H) spiroperidol. Brain Res 136:578-584.
23. Finotti P and Palatini P (1981) Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium activated adenosine triphosphatase. J Pharmacol Exp Ther 217:784-790.
24. Funder JW, Feldman D and Edelman IS (1973) The role of plasma binding and receptor specificity in the mineralcorticoid action of aldosterone. Endocrinology 92:994-999.
25. Gaines KL, Hamilton S and Boyd AE (1988) Characterization of the solfonylurea receptor on beta cell membrane. J Biol Chem 236:2589-2592.
26. Garay RP, Diez J, Nazaret C, Dagher G and Abitbol JP (1985) The interaction of canrenone with the Na,K-pump in human red blood cells. Naunyn-Schmiedeberg's Arch Pharmacol 329:311-315.
27. Gomez-Sanchez EP, Foecking MF, Sellers D, Blankenship MS and Gomez-Sanchez CE (1994) Is the circulating ouabain-like compound ouabain? Am J Hypertens 7:647-650.
28. Gopalakrishnan V, Triggle CR, Sulakhte PV and McNeill JR (1986) Characterization of a specific, high affinity 3H8-arginine vasopressin-binding site in liver microsomes from different strains of rat and the role of magnesium. Endocrinology 118:990-997.
29. 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 55:323-326.
30. Griffiths NM, Ogden PH, Cormack R and Lamb JF (1991) Discrepancy between the short and long term effects of ouabain on the sodium pumps of human cells grown in culture. Br J Pharmacol 104:419-427.
31. Haas E, Goldblatt H, Gipson EC and LaVera L (1966) Extraction, purification and assay of human renin free of angiotensinase. Circ Res 19:739-749.
32. Haddy FJ and Overbeck H (1976) The role of humoral agents in volume expanded hypertension. Life Sci 19:935-948.
33. Hamlyn JM, Ringel R, Schaffer J, Levinson PD, Hamilton BP, Kowarski AA and Blaustein MP (1982) A circulating inhibitor of the Na-K ATPase associated with essential hypertension. Nature (Lond) 300:650-652.
34. 3H)mepyramine to histamine H1 receptors in guinea-pig brain. J Neurochem 31:997-1004.
35. 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature (Lond) 290:149-152.
36. 3H)quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes. J Pharmacol 237:419-427.
37. Huang BS, Huang X, Harmsen E and Leenen FHH (1994) Chronic central versus peripheral ouabain, blood pressure, and sympathetic activity in rats. Hypertension 23(part2):1087-1090.
38. 3H)Mazindol binding associated with neuronal dopamine uptake sites in corpus striatum membranes. Eur J Pharmacol 90:461-462.
39. Jørgensen PL (1974) Purification and characterization of the Na-K ATPase from outer medulla of mammalian kidney. Biochim Biophys Acta 356:36-52.
40. Kelly RA and Smith TW (1992) Is ouabain the endogenous digitalis? Circulation 86(2):694-697.
41. 3H)SCH 23390 identifies D-1 binding sites in rat striatum and other brain areas. J Pharm Pharmacol 38:907-912.
42. Kojima I, Yoshihara S and Ogata E (1982) Involvement of endogenous digitalis-like substance in genesis of deoxycorticosterone-salt hypertension. Life Sci 30:1775-1781.
43. Leenen FHH, Harmsen E and Yu H (1994) Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt-sensitive vs. salt-resistant rats. Am J Physiol 267(36):H1916-H1920.
44. + restoration. Am J Physiol 265: C887-C892.
45. Lewis LK, Yandle TG, Lewis JG, Richards AM, Pidgeon GB, Kaaja RJ and Nicholls MG (1994) Ouabain is not detectable in human plasma. Hypertension 24:549-555.
46. 3H-ligand for serotonin 2 receptor binding sites. Mol Pharmacol 21:301-305.
47. Lindsay R and Parker JLW (1976) Rat hepatic sodium-potassium ion-dependent adenosine triphosphatase after treatment with digoxin and tyroxine. Clin Sci Mol Med 50:329-332.
48. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
49. Manunta P, Rogowski AC, Hamilton BP and Hamlyn JM (1994) Ouabain-induced hypertension in the rat: Relationships among plasma and tissue ouabain and blood pressure. J Hypertens 12:549-560.
50. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA and Ludens JH (1991) Mass spectral characterization of an endogenous digitalis-like factor from human plasma. Hypertension 17:930-935.
51. Mihara S, Hara S, Ueda M, Ide M and Fujimoto M (1989) Comparison of vascular and platelet thromboxane A2/prostaglandin H2 receptors in the pig. Eur J Pharmacol 160:313-321.
52. Mihara SI, Nakajima S, Matumura S, Kohonoike T and Fujimoto M (1994) Pharmacological characterization of a potent non-peptide endothelin receptor antagonist, 97-139. J Pharmacol Exp Ther 268:1122-1128.
53. Moreth K, Renner D and Schoner W (1987) A quantitative receptor assay for "digitalis-like" compounds in serum. Demonstration of raised concentrations in essential hypertension and correlation with arterial blood pressure. Klin Wochensehr 65:179-184.
54. Motulsky HJ and Ransnas LA (1987) Fitting curves to data using nonlinear regression. FASEB J 1:365-374.
55. Noel F and Godfraind T (1984) Heterogeneity of ouabain specific binding sites and Na-K ATPase inhibition in microsomes from rat heart. Biochem Pharmacol 33: 47-53.
56. Pamnani MB, Burris JF, Jemionek JF, Huot SJ, Price M, Freis ED and Haddy FJ (1989) Humoral Na-K pump inhibitory activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 2:524-531.
57. Pamnani MB, Whitehorn WV, Clough DL and Haddy FJ (1990) Effects of Canrenone on blood pressure in rats with reduced renal mass. Am J Hypertens 3:188-195.
58. 3H)adenosine. Brain Res 237:203-214.
59. Philibert D, Ojasoo T and Raynaud JP (1977) Properties of cytoplasmic progestin-binding protein in the rabbit uterus. Endocrinology 101:1850-1854.
60. Pidgeon GB, Richards MA, Nicholls GM, Charles CJ, Rademaker MT, Lynn KL, Bailey RR, Lewis LK and Yandle TG (1996) Chronic ouabain infusion does not cause hypertension in sheep. Am J Physiol 270:E386-E392.
61. Pita J, Lippman ME, Thompson EB and Loriaux DL (1975) Interaction of spironolactone and digitalis with the 5α-dihydrotestosterone (DHT) receptor of rat ventral prostate. Endocrinology 97:1521-1527.
62. + or ouabain. J Cell Physiol 106:85-97.
63. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, Melloni P, Sputore S and Torri M (1997) 17β-(3-Furyl)-5β-androstane-3β,14β,17α-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 40:1561-1564.
64. +-ATPase inhibition. J Biol Chem 268, 12:8851-8854.
65. +-ATPase regulation. J Biol Chem 260, 23:12740-12743.
66. +-ATPase during chronic ouabain treatment. Am J Physiol 256:C75-C80.
67. 3H)Verapamil binding sites in brain and skeletal muscle: Regulation by calcium. Eur J Pharmacol 95:319-321.
68. Rifka SM, Pita JC and Loriaux DL (1976) Mechanisms of interaction of digitalis with estradiol binding sites in rat uteri. Endocrinology 99:1091-1098.
69. Rossi GP, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A and Pessina AC (1995) Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: Relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 13:1181-1191.
70. 3H)Diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex. Eur J Pharmacol 11:273-277.
71. Shain SA and Boesel RW J (1975) Saturation analysis of the binding of androgens, antiandrogens and estrogens by the cytoplasmic high affinity androgen receptor of the rat ventral prostate. Steroid Biochem 6:43-50.
72. Shleikh SP, O'Hare MM, Tortroa O and Schwartz TW (1989) Binding of monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cells. J Biol Chem 246:6648-6654.
73. 3H)flunitrazepam binding. Life Sci 24:351-358.
74. Sweadner KJ (1989) Isoenzymes of the Na-K ATPase. Biochim Biophys Acta 988: 185-220.
75. +-ATPase isoforms in myocardium. Isoform change in deoxycorticosterone acetate-salt hypertension. Circ Res 74:669-678.
76. +-ATPase α- and β-subunit mRNA and protein abundance in cultured renal proximal tubule cells. Am J Physiol 263:C436-C442.
77. U'Prichard DC, Greenberg DA and Snyder SH (1977) Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol 13:454-473.
78. Vazquez J, Feigenbaum P, Katz G, King VF, Reuben JP, Roy-Contancin L, Sloughter RS, Kaczorowski GJ and Garcia ML (1989) Characterization of high affinity binding sites for carybdotoxin in sarcolemma membranes from bovine aortic smooth muscle. Evidence for a direct association with the high conductance calcium-activated potassium channel. J Biol Chem 264:20902-20909.
79. +-ATPase activity in rat tissues. Int J Cardiol 40:95-100.
80. 3H)AF-DX 116 labels subsets of muscarinic cholinergic receptors in rat brain and heart. Life Sci 41:1571-1760.
81. Whitebread SE, Taylor V, Bottari SP, Kamber B and de Gasparo M (1991) Radioiodinated CGP-42112A: A novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. Biochem Biophys Res Comm 181: 1365-1371.
82. Whorwood CB, Ricketts ML and Steward PM (1994) Regulation of sodium-potassium adenosine triphosphate subunit gene expression by corticosteroids and 11-β-hydroxysteroid dehydrogenase activity. Endocrinology 135 (3):901-910.
83. Williams D, Jones K, Pittibone D, Lio E and Clineshmidt B (1991) Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Comm 175:556-561.
84. Yoda A and Yoda S (1977) Association and dissociation rate constant of the complexes between various cardiac aglycones and sodium- and potassium-dependent adenosine triphosphatase formed in the presence of magnesium and phosphate. Mol Pharmacol 13:352-361.
85. Zhao N, Lo LC, Berova N, Nakanishi K, Tymiak A, Ludens JH and Haupert GT (1995) Na-K ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: Nanogram scale CD structural analysis. Biochemistry 34:9893-9896.